Technical Analysis for VRPX - Virpax Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
D 0.73 -0.83% -0.01
VRPX closed down 0.83 percent on Friday, November 1, 2024, on 16 percent of normal volume. It was able to find support at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
Weak + Overbought Other 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish -0.83%
MACD Bullish Centerline Cross Bullish -0.83%
Weak + Overbought Other -0.83%
Wide Bands Range Expansion -0.83%
Overbought Stochastic Strength -0.83%
Crossed Above 50 DMA Bullish 1.10%

   Recent Intraday Alerts

Alert Time
10 DMA Support about 22 hours ago
50 DMA Support about 22 hours ago
Down 5% about 22 hours ago
Fell Below Previous Day's Low about 22 hours ago
Down 3% 1 day ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Virpax Pharmaceuticals, Inc. Description

Virpax Pharmaceuticals, Inc. develops and manufactures non-opioid and non-addictive based drug compounds and drug delivery systems for pain management. It offers products, such as Probudur, an injectable bupivacaine hydrogel for postoperative pain management; Epoladerm, a diclofenac metered-dose spray film for acute musculoskeletal pain; and NES100, an endogenous enkephalin intranasal spray for acute and chronic spray. The company develops drug delivery technologies, such as Topical metered-dose spray, Liposomal in Hydrogel encapsulation, and Enkephalin Intranasal spray. It also develops therapies to manage post-traumatic stress disorder (PTSD), as well as to help prevent viral spread, including influenza and SARS-CoV-2 (Covid-19). Virpax Pharmaceuticals, Inc. was founded in 2016 and is based in Malvern, Pennsylvania.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Health Sciences Drugs Euphoriants Opioids Influenza Pain Management Drug Delivery Analgesics Morphinans Post Traumatic Stress Disorder Heroin Drug Delivery Systems Morphine Bupivacaine Nasal Administration

Is VRPX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.0
52 Week Low 0.3625
Average Volume 203,275
200-Day Moving Average 1.90
50-Day Moving Average 0.69
20-Day Moving Average 0.60
10-Day Moving Average 0.68
Average True Range 0.09
RSI (14) 57.08
ADX 21.52
+DI 27.05
-DI 17.64
Chandelier Exit (Long, 3 ATRs) 0.52
Chandelier Exit (Short, 3 ATRs) 0.62
Upper Bollinger Bands 0.81
Lower Bollinger Band 0.39
Percent B (%b) 0.81
BandWidth 68.54
MACD Line 0.01
MACD Signal Line -0.01
MACD Histogram 0.0247
Fundamentals Value
Market Cap 8.52 Million
Num Shares 11.7 Million
EPS -1.17
Price-to-Earnings (P/E) Ratio -0.62
Price-to-Sales 0.00
Price-to-Book 0.67
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.88
Resistance 3 (R3) 0.87 0.82 0.85
Resistance 2 (R2) 0.82 0.78 0.82 0.84
Resistance 1 (R1) 0.77 0.75 0.74 0.78 0.84
Pivot Point 0.72 0.72 0.70 0.72 0.72
Support 1 (S1) 0.67 0.68 0.64 0.68 0.62
Support 2 (S2) 0.62 0.65 0.62 0.61
Support 3 (S3) 0.57 0.62 0.60
Support 4 (S4) 0.58